ACTIVITY TITLE: Removal of myomas in asymptomatic patients to improve fertility and/or reduce
miscarriage rate: A guideline
The American Society for Reproductive Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
The American Society for Reproductive Medicine designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Release Date: September 7th, 2017
Expiration Date: September 7th, 2020
Estimated Time to Complete Activity: 95 minutes
NEEDS ASSESSMENT and IDENTIFICATION OF PRACTICE GAP:
The purpose of this module is to present a systematic review to evaluate if uterine myomas impact the likelihood of pregnancy and pregnancy loss, and if myomectomy influences pregnancy outcomes in asymptomatic women. The educational need for this activity was based on the 2014 gap analysis review by the ASRM CME Committee indicating a need for educational materials concerning fibroids and tumors of the reproductive tract.
Note: this activity contains interactive case questions.
At the conclusion of the educational activity, participants should be able to:
1. Discuss if uterine myomas impact the likelihood of pregnancy and pregnancy loss.
2. Discuss if myomectomy influences pregnancy outcomes in asymptomatic women.
This activity is designed to meet the educational needs of physicians and allied health professionals involved in assisted reproductive technology.
SUCCESSFUL COMPLETION REQUIREMENTS
Successful completion of this educational activity requires the learner to:
· View a course overview page, containing all CME and disclosure information, including acknowledgement of commercial support and disclosure of unlabeled use, prior to the start
of each module.
· Complete an 8-question pre-exam prior to the module. Learners should note any pre-exam questions answered incorrectly for clarification during module study.
· Be given the option of downloading a printed syllabus containing the presentation.
· Participate in the interactive activity, answering the interactive questions within the program.
Each question has unlimited attempts and must be answered correctly to proceed in the activity.
· Complete an 8-question post-exam, with feedback of correct/incorrect answers, scoring a minimum of 70%.
· Complete the evaluation survey.
· Print certificate of completion.
DISCLOSURES FOR PLANNERS AND FACULTY
Contributors and Reviewers
The following members of the ASRM Practice Committee participated in the development of this document. All Committee members disclosed commercial and financial relationships with manufacturers or distributors of goods or services used to treat patients. Members of the Committee who were found to have conflicts of interest based on the relationships disclosed did not participate in the discussion or development of this document.
Samantha Pfeifer, MD – Consultant: Best Doctors
Kristin Bendikson, M.D. - Theralogix, Medical Board member, Consultant.
Samantha Butts, MD – Nothing to Disclose
Christos Coutifaris, M.D. – Nothing to Disclose
Tommaso Falcone, M.D. – Nothing to Disclose
Clarisa Gracia, MD, MSCE – Nothing to Disclose
Karl Hansen, M.D., Ph.D. – Nothing to Disclose
Gregory Fossum, MD- Intuitive Surgical: Speakers Bureau
Jennifer Mersereau, MD – Nothing to Disclose
Randall Odem, MD- Nothing to Disclose
Richard Paulson, M.D.- Nothing to Disclose
Alan Penzias, MD – Counsultant: ReproSource, Inc, OvaScience; Board Member: ReproSource, Inc.
Margareta Pisarska, MD- REI Division Member for the American Board of OBGYN; Grant/Research: NIH, ASRM; Speakers Bureau: OvaScience; ABOG.
Robert Rebar, MD- Contributing editor, Journal Watch Women's Health
Mitchell Rosen, MD- OvaScience
Jay Sandlow, MD- Nothing to Disclose
Michael Vernon, PhD: Nothing to Disclose
This report was developed under the direction of the Practice Committee of the American Society for Reproductive Medicine as a service to its members and other practicing clinicians. Although this document reflects appropriate management of a problem encountered in the practice of reproductive medicine, it is not intended to be the only approved standard of practice or to dictate an exclusive course of treatment. Other plans of management may be appropriate, taking into account the needs of the individual patient, available resources, and institutional or clinical practice limitations. The Practice Committee and the Board of Directors of the American Society for Reproductive Medicine have approved this report.
The content has been reviewed for conformity with ACCME Essentials, Policies and Standards for Commercial Support. All faculty/authors participating in this activity were required to disclose any relationships they may have with commercial entities whose products or services are used to treat patients so that participants may evaluate the objectivity of the presentations. Any discussion of off-label, experimental, or investigational use of drugs or devices will also be disclosed.
STATEMENT OF SUPPORT
No commercial support has been provided for this activity.